(UTMD) Utah Medical Products - Ratings and Ratios

Utah Medical Products, Inc. is a leading provider of specialized medical devices catering to the global healthcare industry, with a diverse product portfolio that includes fetal monitoring accessories, vacuum-assisted delivery systems, and various other medical tools for labor and delivery, neonatal care, womens health, and other medical specialties.

The companys extensive range of products is designed to meet the specific needs of healthcare professionals, including fetal monitoring accessories, neonatal respiratory care devices, blood pressure monitoring systems, and a variety of catheterization and surgical instruments, as well as devices for gynecological procedures and womens health.

With a strong presence in the US market and a global reach, Utah Medical Products, Inc. serves a wide range of healthcare settings, including neonatal intensive care units, labor and delivery departments, womens health centers in hospitals, outpatient clinics, and physicians offices, leveraging its expertise to provide innovative solutions that enhance patient care.

Analyzing the , we observe that UTMDs stock price is currently at $54.71, with a 20-day SMA of $52.98, indicating a recent uptrend. The 50-day SMA is at $55.03, and the 200-day SMA is at $61.66, suggesting a potential long-term downtrend. The ATR is 1.41, representing a 2.57% daily volatility. The stock is currently trading near its 52-week low of $51.75, having peaked at $73.99. Based on this technical analysis, we can anticipate a potential rebound or consolidation in the near term.

Examining the , UTMD has a market capitalization of $171.61M USD, with a P/E ratio of 13.80, indicating a relatively undervalued stock. The Return on Equity (RoE) is 10.73%, suggesting a decent profitability. By combining these fundamental insights with the technical analysis, we can forecast that UTMD may experience a moderate price increase in the coming months, potentially reaching $60-$65, driven by its stable product portfolio, diversified customer base, and potential rebound from its current undervalued state.

Taking into account both the technical and fundamental analysis, a potential investment strategy could involve accumulating UTMD shares at current levels, with a target price of $60-$65, and a stop-loss below $51.75, to capitalize on the anticipated rebound and potential long-term growth.